Scarica l'app Stockscreener
1.49
3.87%
-0.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Precedente Chiudi:
$1.55
Aprire:
$1.57
Volume 24 ore:
699.61K
Relative Volume:
0.55
Capitalizzazione di mercato:
$32.59M
Reddito:
$752.00K
Utile/perdita netta:
$-68.21M
Rapporto P/E:
-0.1536
EPS:
-9.6977
Flusso di cassa netto:
$-58.21M
1 W Prestazione:
+0.68%
1M Prestazione:
-5.70%
6M Prestazione:
-52.09%
1 anno Prestazione:
-33.63%
Intervallo 1D:
$1.47
$1.615
Intervallo di 1 settimana:
$1.44
$1.7983
Portata 52W:
$1.17
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Nome
Bioxcel Therapeutics Inc
Settore
Telefono
203-643-8060
Indirizzo
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.49 | 32.59M | 752.00K | -68.21M | -58.21M | -9.6977 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.62 | 48.81B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.67B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.57 | 33.27B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
536.12 | 23.50B | 3.18B | 1.33B | 1.04B | 27.90 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-21 | Downgrade | UBS | Buy → Neutral |
| 2023-08-15 | Downgrade | Mizuho | Buy → Neutral |
| 2023-07-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-03-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-01 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-06 | Reiterato | BofA Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-30 | Iniziato | Goldman | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-04 | Iniziato | Guggenheim | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
Mostra tutto
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
BioXcel Therapeutics closes $8M registered direct offering - Investing.com Australia
How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs - Yahoo Finance
BioXcel Therapeutics raises $8M in stock offering - Hartford Business Journal
BioXcel Therapeutics Announces Registered Direct Offering and Warrant Amendment – SEC 8-K Filing March 2026 - Minichart
BioXcel Therapeutics Announces Registered Direct Equity Financing - TipRanks
BioXcel Therapeutics, Inc. Completes $8 Million Registered Direct Offering of Common Stock and Warrants - Quiver Quantitative
BioXcel Therapeutics Closes $8.0 Million Direct Offering - marketscreener.com
AI-driven drugmaker BioXcel raises $8M, extends investor warrants - Stock Titan
BioXcel Therapeutics raises $8M in registered direct offering - Investing.com Australia
BioXcel Therapeutics (NASDAQ: BTAI) raises ~$7.3M with 2.48M share offering - Stock Titan
BTAI Forecast, Price Target & Analyst Ratings | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering - Bitget
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering - GlobeNewswire Inc.
BioXcel Therapeutics raises $8M in registered direct offering By Investing.com - Investing.com Nigeria
Aug Technicals: Is BioXcel Therapeutics Inc benefiting from interest rate changesQuarterly Risk Review & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Why did BTAI stock surge 20% in pre-market today? - MSN
Why Are BioXcel Therapeutics Shares Down Friday? - Benzinga
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal - Sahm
BioXcel Therapeutics Seeks Market Expansion amid Financial Struggles - timothysykes.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
BioXcel Therapeutics Stock Soars Amid New Drug Approval Speculation - StocksToTrade
BTAI Stock Gained 5% TodayWhat's The Latest On Its Opioid Withdrawal Treatment? - Stocktwits
BioXcel Therapeutics (BTAI) Target Price Lowered by HC Wainwrigh - GuruFocus
BioXcel Therapeutics shares rise 2.7% as experimental opioid withdrawal drug shows benefit in mid-stage trial - marketscreener.com
BioXcel Therapeutics Achieves Milestone with Igalmi’s Market Study - timothysykes.com
BioXcel Therapeutics Stock Rallies Opioid Study Success - Benzinga
Why Did BTAI Stock Surge 20% In Pre-Market Today? - Asianet Newsable
BioXcel Therapeutics (BTAI) Reports Promising Phase 2 Results fo - GuruFocus
BTAI Stock Surges Pre-Market After On Positive Trial Results For Opioid Withdrawal Treatment - Stocktwits
BioXcel Therapeutics shares rise 21.1% premarket as experimental opioid withdrawal drug shows benefit in mid-stage trial - marketscreener.com
BioXcel Therapeutics rises amid sector rotation - Intellectia AI
Bioxcel Therapeutics announces positive Phase 2 topline results from Columbia University-led study of BXCL501 for treatment of opioid withdrawal - marketscreener.com
BioXcel reports positive Phase 2 data for opioid withdrawal drug By Investing.com - Investing.com UK
Bioxcel Therapeutics Announces Positive Phase 2 Topline Results From Columbia University-Led Study Of BXCL501 For Treatment Of Opioid Withdrawal - TradingView
BioXcel Therapeutics Announces Positive Phase 2 Topline - GlobeNewswire
BTAI PE Ratio & Valuation, Is BTAI Overvalued - Intellectia AI
BTAI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AI Drugmaker BioXcel Eyes $9.8M Investor Settlement - Law360
BTAI SEC FilingsBioxcel Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BioXcel Submits sNDA for Igalmi to Treat Agitation - Intellectia AI
Is BioXcel Therapeutics Inc. stock good for income investorsJuly 2025 Rallies & Risk Controlled Stock Alerts - mfd.ru
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia - Bitget
BioXcel Therapeutics (BTAI) Hosts Roundtable on Acute Agitation in Alzheimer's - GuruFocus
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia - The Manila Times
Doctors tackle 100M Alzheimer’s agitation episodes in new BioXcel webcast - Stock Titan
BioXcel Therapeutics to Host Virtual Roundtable Featuring - GlobeNewswire
Why BioXcel Therapeutics Inc. stock is favored by pension fundsJuly 2025 Macro Moves & Advanced Technical Analysis Signals - mfd.ru
Aug Weekly: Is BioXcel Therapeutics Inc gaining market shareTrade Exit Report & Safe Swing Trade Setups - baoquankhu1.vn
BioXcel Therapeutics Reports Successful Primary Endpoint Achievement in SERENITY At-Home Phase 3 Safety Trial, Supporting sNDA for IGALMI® Label Expansion - Intellectia AI
Can BioXcel Therapeutics Inc. stock hit record highs againBond Market & Weekly Breakout Opportunity Watchlist - mfd.ru
BTAI Should I Buy - Intellectia AI
Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
3.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):